In the clinical settings, it has been reported that tumor‐infiltrating CD4‐positive T lymphocytes [8], peripheral CD62 low CD4‐positive T lymphocytes [22], and peripheral CD4‐positive memory T lymphocytes [23] are associated with the efficacy of immune checkpoint inhibitors in patients with NSCLC. Here, CD4 is linked to neoplasm.